General Intermediates Successfully Completes Government of Canada Funded Pharmaceutical Project
Edmonton's GIC Completes Research Program for a new API Starting Material
Edmonton’s General Intermediates of Canada Inc. (GIC) announced they have successfully completed a research project related to a key starting API material for a global pharmaceutical client. This project was done with the support of the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP.)
GIC has taken the 2-chloro-5-hydroxy (2C5H) pyrimidine molecule and developed a novel synthesis route which enables the molecule to be manufactured economically, in commercial quantities, at purity levels not previously seen in the industry. Although this molecule was long of interest to the global pharmaceutical industry, it was not economically feasible for commercialization prior to GIC’s work.
“In addition to helping our client with quality and repeatability regarding 2C5H, our work in process refinement and the production of difficult small molecules in metric tonne quantities has led to other contract manufacturing opportunities,” said Dr. Glenn Weagle. “The support of IRAP was key to our success.”